The Medicines Company Appoints Elizabeth Wyatt to Board of Directors

    Medical Writers/Business Editors/Health Writers
    BIOWIRE2K

    PARSIPPANY, N.J.--(BUSINESS WIRE)--April 5, 2005--The Medicines Company (NASDAQ: MDCO) today announced the appointment of Elizabeth H.S. Wyatt to the Company's Board of Directors. Ms. Wyatt has 20 years of experience with Merck & Co., Inc., where she held positions of increasing responsibility for business development and licensing before her retirement in 2000 as Vice President, Corporate Licensing. She currently serves on the Board of Directors of Neose Technologies, Ariad Pharmaceuticals, and MedImmune, Inc. She is also on the Board of Trustees of Randolph-Macon College.
    Clive Meanwell, Chairman and Chief Executive Officer of The Medicines Company, stated, "I'd like to welcome Elizabeth to The Medicines Company's Board. We expect her experience, particularly in areas of general management and business development, to enhance the Board, as The Medicines Company works toward leadership in acute hospital care medicine."
    The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax(R) (bivalirudin), an anticoagulant approved in the U.S. and other countries for use in patients undergoing percutaneous transluminal coronary angioplasty (PTCA) procedures. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators. The Company's website is http://www.themedicinescompany.com.

    Statements contained in this press release about our position and the success of our products in the marketplace, the development of our products and the acquisition of additional products, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Some of the important factors that may cause or contribute to such differences include the commercial success of Angiomax, whether the Company's products will advance in the clinical trials process, whether the Company's products will receive approval from regulatory agencies, physicians' acceptance of clinical trial results, and the Company's ability to identify, select and acquire additional product candidates, as well as the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission, including without limitation the Company's Annual Report on Form 10-K filed on March 14, 2005. We specifically disclaim any obligation to update these forward-looking statements.

--30--MW/ny*

CONTACT: The Medicines Company Michael Mitchell, 973-656-1616 investor.relations@themedco.com

KEYWORD: NEW JERSEY INDUSTRY KEYWORD: PHARMACEUTICAL MEDICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: The Medicines Company

Copyright Business Wire 2005